SGC Stimulation, Perioperative Vascular Reactivity, and Organ Injury in Cardiac Surgery
The Effects of Soluble Guanylyl Cyclase Stimulation on Perioperative Vascular Reactivity and Organ Injury in Cardiac Surgery
Vanderbilt University Medical Center
170 participants
May 19, 2023
INTERVENTIONAL
Conditions
Summary
The goal of this mechanistic clinical trial is to learn about the effects of medications called soluble guanylyl cyclase stimulators on vascular function and markers of kidney and brain injury in patients having heart surgery. The main questions it aims to answer are: 1. Does soluble guanylyl cyclase stimulation improve blood vessel function compared to placebo? 2. Does soluble guanylyl cyclase stimulation decrease markers of kidney injury and brain injury compared to placebo? Participants will be randomized to a soluble guanylyl cyclase stimulator called vericiguat or placebo, and researchers will compare vascular function and markers of brain and kidney injury to see if vericiguat improves vascular function and reduces markers of injury. This will provide important information to determine the underlying reasons that patients have some kidney and brain function problems after having heart surgery.
Eligibility
Inclusion Criteria2
- Age ≥18 years
- Elective open-heart surgery, defined as surgery on the heart or aorta that requires sternotomy or thoracotomy
Exclusion Criteria14
- Intolerance to vericiguat
- Use of other soluble guanylyl cyclase stimulators or current use of phosphodiesterase-5 inhibitors
- Pregnancy or breast feeding. Pregnancy will be excluded in women of child-bearing potential by a urine or serum beta hcg test
- Renal replacement therapy within 30 days prior to screening
- Estimated glomerular filtration rate \<15 ml/min per 1.73 m2 per Chronic Kidney Disease Epidemiology collaboration (CKD-EPI) equation at time of screening
- Systolic blood pressure less than 120 mmHg at the time of screening
- Prior kidney transplantation
- History of significant liver dysfunction (defined as Child-Pugh class C)
- Surgery scheduled to be performed with circulatory arrest
- Surgery scheduled to correct a major congenital heart defect
- Extracorporeal membrane oxygenation (ECMO) prior to surgery
- Active systemic infection or surgery for infectious endocarditis
- Ventricular assist device or intraaortic balloon pump support prior to surgery
- Prisoners
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Vericiguat 10 mg administered orally starting 2 days prior to heart surgery through the day of surgery
Matched placebo administered orally starting 2 days prior to heart surgery through the day of surgery
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05812755